Login to Your Account

First patient dosed in Advaxis’ phase III cervical cancer trial

By Michael Fitzhugh
Staff Writer

Tuesday, February 7, 2017

A phase III trial testing the ability of Advaxis Inc.’s lead immunotherapy candidate, axalimogene filolisbac, to improve disease-free survival among patients with high-risk locally advanced cervical cancer has enrolled and dosed its first patient. The FDA fast-tracked study, called AIM2CERV, is expected to enroll 450 patients and is being run under a special protocol assessment.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription